ALTEOGEN (196170) Q2 2026 earnings summary

Executive summary

• Operates in biopharmaceutical R&D, production, and sales, focusing on proprietary platform technologies for subcutaneous drug delivery and next-generation biologics.

• Major revenue from licensing out core technologies (ALT-B4, biosimilars) to global pharma partners, with upfront, milestone, and royalty income.

• Recent product launches and regulatory approvals in Korea, China, and Europe for biosimilars and proprietary drugs.

Financial highlights

• 2026 H1 consolidated revenue: ₩140.5B, down from ₩215.9B in 2025 H1.

• Operating income: ₩73.5B (2025 H1: ₩106.9B); net income: ₩101.3B (2025 H1: ₩145.2B).

• Gross margin remains strong; basic EPS for H1 2026: ₩1,871.

• Cash and cash equivalents at period end: ₩80.4B.

Outlook and guidance

• Expects continued stable cash inflow from existing and new licensing deals.

• Ongoing expansion of product pipeline and global regulatory submissions for biosimilars and new biologics.

• Plans to invest in commercial-scale manufacturing facilities.